The virtual showroom will provide real-time construction updates, various specs, and services that its new super plant, Plant 4, will offer upon completion.
Samsung Biologics announced on Dec. 4, 2020 that it is launching a virtual showroom to showcase key features of its new super plant, Plant 4.
The virtual showroom will provide real-time construction updates, various specs, and services that the new plant will offer upon completion, while also allowing the company to connect with clients interested in the plant’s progression, a company press release said. Construction started on the new plant in November 2020, and it is expected to be the world’s largest and most innovative bio-manufacturing facility of its kind, the company said in its press release.
“Our new super plant and our virtual showroom are a direct response to an accelerated demand in the industry for both traditional and digitally enabled services. By leveraging the latest innovation, Plant 4 will provide easy and secure access to manufacturing and quality information whenever customers require it and deliver the highest levels of client satisfaction and regulatory compliance,” said Dr. Tae Han Kim, CEO of Samsung Biologics, in the press release. “Our Plant 4 Virtual Showroom also exemplifies Samsung Biologics’ latest efforts to lead the industry in the digital revolution for enhanced connectivity and agility in responding to our clients, partners, and shareholders.”
Source: Samsung
Benuvia Granted GMP Certification by Brazil National Health Surveillance Agency
March 14th 2025The certification allows Benuvia to produce pharmaceutical products for companies, either local to Brazil or international, that may be looking for compliant and high-quality production capabilities in the Brazilian pharmaceutical market.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.